| Name | Wy 49051 |
| Description | Wy 49051 is an orally active antagonist of H1 receptor(IC50 of 44 nM). |
| In vitro | Wy 49051 showed a great inhibitory effect on H1. At a concentration of 100 nM, it produced 92% inhibition of histamine-induced guinea pig ileal contraction. Wy 49051 is the most effective compound, with 700 times the potency of astemizole and 470 times the potency of hydroquinone. Wy 49051 also has high affinity for α1 receptor with IC50 of 8 nM[1]. |
| In vivo | Wy 49051 demonstrates efficacy in counteracting histamine-induced lethality in guinea pigs, with effective doses (ED50) of 1.91 mg/kg orally (po), 0.70 mg/kg intraperitoneally (ip), and 0.01 mg/kg intravenously (iv). Additionally, the compound maintains its oral efficacy without any reduction for up to 18 hours posttreatment[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (10.25 mM), Sonication is recommended.
DMSO : 45 mg/mL (92.29 mM), Sonication is recommended.
|
| Keywords | Wy 49051 | HistamineReceptor | Histamine Receptor | H1 receptor |
| Inhibitors Related | Undecane | Betahistine mesylate | Histamine dihydrochloride | Meclizine dihydrochloride | Lidocaine | Famotidine | Sodium butanoate | Nizatidine | Alginic acid | Mianserin hydrochloride | Trazodone hydrochloride | Doxepin hydrochloride |
| Related Compound Libraries | Histamine & Melatonin Receptor-Targeted Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Neurotransmitter Receptor Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library |
United States
